Since then, preclinical models or early-stage clinical studies have addressed the potential of conjugating transferrin to chemotherapeutics [11, 12], drug-carrying nanoparticles [9, 22–24], and optical [25–27] or radioactive [8, 10] tracers to target breast cancer. This evidence concerns the gene TF and breast cancer.